Skip to main content

Full Schedule

Full Schedule

  • Friday, May 5, 2023
  • 9:00 AM – 9:15 AM ET
    Welcome and Introduction
  • 9:15 AM – 9:50 AM ET
    Session 16: HER2-Positive Metastatic Breast Cancer: Where Are We Headed?
  • 9:50 AM – 10:00 AM ET
    Live Q&A
  • 10:00 AM – 10:15 AM ET
    Break
  • 10:15 AM – 11:15 AM ET
    Case-Based Discussion on Management of Select Adverse Events
  • 11:15 AM – 11:30 AM ET
    Break
  • 11:30 AM – 12:05 PM ET
    Session 17: Immunotherapy for Breast Cancer
  • 12:05 PM – 12:15 PM ET
    Live Q&A
  • 12:15 PM – 12:30 PM ET
    Break
  • 12:30 PM – 1:15 PM ET
    Session 18: ER-Positive Targeted Therapy: PI3, AKT, mTOR, etc
  • 1:15 PM – 1:35 PM ET
    Break
  • 1:35 PM – 1:50 PM ET
    Session 19: Debate: Are All CDK4/6 Inhibitors Created Equal? - YES
  • 1:50 PM – 2:05 PM ET
    Session 19: Debate: Are All CDK4/6 Inhibitors Created Equal? - NO
  • 2:05 PM – 2:25 PM ET
    Session 19: Debate: Are All CDK4/6 Inhibitors Created Equal? - DISCUSSION
  • 2:20 PM – 2:45 PM ET
    Break
  • 2:45 PM – 3:20 PM ET
    Session 20: Beyond Immunotherapy: Novel Agents in TNBC
  • 3:20 PM – 3:30 PM ET
    Live Q&A
  • 3:30 PM – 3:45 PM ET
    Break
  • 3:45 PM – 4:20 PM ET
    Session 21: Biosimilars in Breast Cancer Therapy
  • 4:20 PM – 4:30 PM ET
    Live Q&A
  • 4:30 PM – 4:45 PM ET
    Break
  • 4:45 PM – 5:20 PM ET
    Session 22: HER2-Low Breast Cancer: Limits of Testing and Where to Go from Here
  • 5:20 PM – 5:30 PM ET
    Live Q&A